Research on self-management status quo and influencing factors of patients with non-alcoholic fatty liver disease
LIANG Haili1,2 WANG Hui1,2 WANG Ting1,2 TAO Junxiu1,2 ZHOU Qiong1,2 ZHANG Chuhua1,2
1.Department of Hepatology, Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei Province, Wuhan 430061, China;
2.Hubei Provincial Institute of Traditional Chinese Medicine, Hubei Province, Wuhan 430074, China
Abstract:Objective To investigate the self-management situation and influencing factors of patients with nonalcoholic fatty liver disease (NAFLD). Methods Using the convenient sampling method, a total of 217 patients with NAFLD were recruited from the hepatology research clinic of a top three hospital in Wuhan from March to August 2017. The self-management scale, the chronic illness resources survey (CIRS) and general self-efficacy scale (GSES) were used to investigated the patients. Results In self-management of NAFLD patients, the scores of daily life management were (32.36±4.72) points. There were statistically significant differences in the self-management scores of patients with NAFLD in different genders, education degrees and annual income (P < 0.05). The self-management level of patients with NAFLD was positively correlated with various dimensions of chronic disease resource utilization and general self-efficacy (r > 0, P < 0.05). Annual income, gender, workplace, organizational structure, health care team and media policies, and general self-efficacy were the main factors affecting NAFLD self-management (P < 0.05). Conclusion The self-management level of patients with NAFLD is affected by many factors. Nursing staff should implement targeted interventions against controllable factors to promote patient enhancing the level of self-management.
梁海莉1,2 王晖1,2 汪婷1,2 陶军秀1,2 周琼1,2 张楚华1,2. 非酒精性脂肪性肝病患者自我管理现状及影响因素分析[J]. 中国医药导报, 2020, 17(20): 46-49,53.
LIANG Haili1,2 WANG Hui1,2 WANG Ting1,2 TAO Junxiu1,2 ZHOU Qiong1,2 ZHANG Chuhua1,2. Research on self-management status quo and influencing factors of patients with non-alcoholic fatty liver disease. 中国医药导报, 2020, 17(20): 46-49,53.